Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David James

Showing results (621-630 of 763) with videos related to

Pageof 77
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 30, 2018
Methylation-dependent Tissue Factor Suppression Contributes to the Reduced Malignancy of IDH1-mutant GliomasDusten Unruh, Snezana Mirkov, Brian Wray, et al.
Oncoimmunology|April 18, 2022
Cell-directed aptamer therapeutic targeting for cancers including those within the central nervous systemJun Wei, Renduo Song, Aria Sabbagh, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 16, 2012
Cooperative interactions of BRAFV600E kinase and CDKN2A locus deficiency in pediatric malignant astrocytoma as a basis for rational therapyEmmanuelle Huillard, Rintaro Hashizume, Joanna J Phillips, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 7, 2022
Regulation of TORC1 by MAPK Signaling Determines Sensitivity and Acquired Resistance to Trametinib in Pediatric BRAFV600E Brain Tumor ModelsFuyang Li, Kathryn M Bondra, Samson Ghilu, et al.
Neuro-Oncology|December 6, 2013
Targeting Wee1 for the treatment of pediatric high-grade gliomasSabine Mueller, Rintaro Hashizume, Xiaodong Yang, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 25, 2021
Neural stem cells secreting bispecific T cell engager to induce selective antiglioma activityKatarzyna C Pituch, Markella Zannikou, Liliana Ilut, et al.
Liver Cancer|December 14, 2017
Treatment Stage Migration Maximizes Survival Outcomes in Patients with Hepatocellular Carcinoma Treated with Sorafenib: An Observational StudyClarence Yen, Rohini Sharma, Lorenza Rimassa, et al.
Journal of Neuro-Oncology|November 18, 2008
Evaluation of MGMT promoter methylation status and correlation with temozolomide response in orthotopic glioblastoma xenograft modelGaspar J Kitange, Brett L Carlson, Ann C Mladek, et al.
Frontiers in Oncology|December 12, 2022
Dinaciclib as an effective pan-cyclin dependent kinase inhibitor in platinum resistant ovarian cancerDavid Howard, David James, Jezabel Garcia-Parra, et al.
Oncotarget|October 8, 2016
Concurrent MEK targeted therapy prevents MAPK pathway reactivation during BRAFV600E targeted inhibition in a novel syngeneic murine glioma modelStefan Grossauer, Katharina Koeck, Nicole E Murphy, et al.
Pageof 77

Showing results (621-630 of 763) with videos related to

Sort By:
Pageof 77
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 30, 2018
Methylation-dependent Tissue Factor Suppression Contributes to the Reduced Malignancy of IDH1-mutant GliomasDusten Unruh, Snezana Mirkov, Brian Wray, et al.
Oncoimmunology|April 18, 2022
Cell-directed aptamer therapeutic targeting for cancers including those within the central nervous systemJun Wei, Renduo Song, Aria Sabbagh, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 16, 2012
Cooperative interactions of BRAFV600E kinase and CDKN2A locus deficiency in pediatric malignant astrocytoma as a basis for rational therapyEmmanuelle Huillard, Rintaro Hashizume, Joanna J Phillips, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 7, 2022
Regulation of TORC1 by MAPK Signaling Determines Sensitivity and Acquired Resistance to Trametinib in Pediatric BRAFV600E Brain Tumor ModelsFuyang Li, Kathryn M Bondra, Samson Ghilu, et al.
Neuro-Oncology|December 6, 2013
Targeting Wee1 for the treatment of pediatric high-grade gliomasSabine Mueller, Rintaro Hashizume, Xiaodong Yang, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 25, 2021
Neural stem cells secreting bispecific T cell engager to induce selective antiglioma activityKatarzyna C Pituch, Markella Zannikou, Liliana Ilut, et al.
Liver Cancer|December 14, 2017
Treatment Stage Migration Maximizes Survival Outcomes in Patients with Hepatocellular Carcinoma Treated with Sorafenib: An Observational StudyClarence Yen, Rohini Sharma, Lorenza Rimassa, et al.
Journal of Neuro-Oncology|November 18, 2008
Evaluation of MGMT promoter methylation status and correlation with temozolomide response in orthotopic glioblastoma xenograft modelGaspar J Kitange, Brett L Carlson, Ann C Mladek, et al.
Frontiers in Oncology|December 12, 2022
Dinaciclib as an effective pan-cyclin dependent kinase inhibitor in platinum resistant ovarian cancerDavid Howard, David James, Jezabel Garcia-Parra, et al.
Oncotarget|October 8, 2016
Concurrent MEK targeted therapy prevents MAPK pathway reactivation during BRAFV600E targeted inhibition in a novel syngeneic murine glioma modelStefan Grossauer, Katharina Koeck, Nicole E Murphy, et al.
Pageof 77